Immunotherapy before surgery — what neoadjuvant treatment is actually meant to do

Neoadjuvant immunotherapy is checkpoint inhibitor immunotherapy given before surgery, in appropriately selected patients, so it can act on the cancer while it is still in place and measurable. It is intended to shrink the tumour and, in a proportion of patients, produce a strong response — information a surgery-first approach cannot provide, because by then the original tumour is already gone.

Most patients who ask about this are not actually eligible for it. It is offered only where a specific cancer type, stage, and biomarker result fall within an approved indication, following review by a multidisciplinary tumour board — it is not a general option to "try immunotherapy first" for any cancer diagnosis, and it is not offered because a patient prefers to delay surgery.

This page sets out why it's given first for the patients who do qualify, whether it delays surgery, and what a pathological response actually tells you — including what happens when the tumour doesn't shrink as hoped.

Most patients diagnosed with cancer do not have this combination of features and proceed directly to surgery instead — that is the common, expected path, not a sign anything was missed in their care.

Yes, by design. Surgery is scheduled after a fixed course of treatment cycles — commonly a period of some months, set out in advance rather than decided cycle by cycle. Response is checked with imaging along the way, and surgery proceeds once that planned window closes.

This is a monitored, time-limited delay, not an open-ended one — your surgical team is involved in setting the schedule from the start, and the operation is not pushed back indefinitely while waiting to see what happens.

Pathological response is what a pathologist finds on examining the tissue removed at surgery — how much viable cancer remains after neoadjuvant treatment. A pathological complete response, meaning no viable cancer is found in the sample, is an encouraging early signal that correlates with outcome in some cancers, per NCCN and ASCO patient-education guidance.

Many patients find this reassuring for a simple reason: it is a concrete laboratory finding, checked directly in the tissue that was removed, not a prediction based on how a scan looked or how a patient felt during treatment. It does not, however, guarantee any individual outcome, and a partial or absent response does not mean treatment failed to help in other ways your surgical and medical oncology team will discuss with you directly.

For the specific cancers and stages where both a neoadjuvant approach and a surgery-first approach are genuinely available, the choice is made by a multidisciplinary tumour board, not applied as a default. Some tumours are borderline operable, and neoadjuvant treatment is used specifically to make surgery more feasible or less extensive; in other cases, proceeding to surgery first and deciding on further treatment afterward, based on the final pathology report, is the equally valid, more established path.

Neither sequence is inherently "better" in the abstract — the right one depends on your specific tumour, its stage, and what your surgical and medical oncology teams agree gives the best combination of surgical outcome and follow-up plan. If the tumour doesn't shrink as hoped during neoadjuvant treatment, surgery still generally proceeds as planned; the operation was never conditional on treatment working perfectly, and your team will reassess the surgical approach with fresh imaging rather than abandon the plan to operate.

• What Is Immunotherapy? How It Differs From Chemotherapy — a plain-language primer if the mechanism above raised more questions than it answered.
• Immunotherapy vs Chemotherapy: Which Is Better for You? — useful if your tumour board is weighing a neoadjuvant chemotherapy protocol alongside or instead of immunotherapy.
• Does Immunotherapy Actually Work? Honest Response Rates — an honest look at response rates generally, for context beyond the pathological response measured in this specific setting.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through this decision, from biopsy review to treatment and surgery coordination.

This page is for general information and does not replace a consultation. Eligibility criteria and treatment timelines described here are general and drawn from NCCN/ASCO patient-education guidance — they are not a prediction of outcome for any individual patient, and do not represent a survival statistic of any kind.

Thousands have asked exactly this before surgery

Wanting to understand why treatment is being recommended before the operation, not after, is not distrust — it's how informed patients make this decision. Our team walks through your specific scans and biopsy report, honestly.